Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;66(9):947-53.
doi: 10.1007/s00228-010-0853-y. Epub 2010 Jun 19.

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system

Sofie Schwan  1 , Anders Sundström, Elisabet Stjernberg, Ebba Hallberg, Pär Hallberg
Affiliations
Free article

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system

Sofie Schwan et al. Eur J Clin Pharmacol. 2010 Sep.
Free article

Abstract

Purpose: Pregabalin is a gamma-aminobutyric acid (GABA) analogue approved for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder. As a GABA analogue, there has been some concern about an abuse liability. We aimed to investigate the possible abuse liability of pregabalin.

Methods: By applying a Bayesian data-mining algorithm to reports of possible drug abuse or addiction in the Swedish national register of adverse drug reactions (SWEDIS), we calculated the information component (IC) for pregabalin and reports of abuse and addiction.

Results: Out of 198 reports indicative of abuse or addiction to any drug, 16 concerned pregabalin. The IC became significantly elevated in the fourth quarter of 2008, rising to 3.99 (95% confidence interval 3.21-4.59) at the end of 2009.

Conclusion: Based on the signal from the present study, we conclude that pregabalin is likely to be associated with an abuse potential.

PubMed Disclaimer

References

    1. J Anxiety Disord. 2004;18(1):1-6 - PubMed
    1. Drug Saf. 2009;32(5):419-27 - PubMed
    1. Eur J Clin Pharmacol. 1998 Jun;54(4):315-21 - PubMed